Eagle Pharmaceuticals (EGRX) Reports Q4 EPS of $0.85, Offers Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.85, versus $0.96 reported last year. Revenue for the quarter came in at $42.3 million, versus $49.9 million reported last year.

GUIDANCE:

Eagle Pharmaceuticals sees Q1 2022 EPS of $3.80-$4.10. Eagle Pharmaceuticals sees Q1 2022 revenue of $120-130 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Rubico to shift from semi-annual to quarterly financial reporting
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk